Tymlos (abaloparatide) received FDA approval for the treatment of postmenopausal osteoporosis in women at high risk for fracture [1][2]. This approval was granted on April 27, 2017 [1].
When does Tymlos patent protection end?
The patent landscape for Tymlos is complex, with various patents covering different aspects of the drug. For detailed information on patent expiry dates and potential challenges, DrugPatentWatch.com provides comprehensive data [3].
What are the approved uses for Tymlos?
Tymlos is indicated to treat postmenopausal women with osteoporosis at high risk for fracture. This includes women who have had a prior fracture that occurred during osteoporosis therapy or whose osteoporosis is not adequately controlled with other available therapies [1][2].
How does Tymlos work to treat osteoporosis?
Tymlos is a parathyroid hormone-related peptide (PTHrP) analog [4]. It works by stimulating bone formation and also decreasing bone resorption, which helps to increase bone mineral density and reduce the risk of fractures [4][5].
What is the difference between Tymlos and Forteo?
Both Tymlos (abaloparatide) and Forteo (teriparatide) are anabolic agents used to treat postmenopausal osteoporosis. While both stimulate bone formation, they are different molecules. Tymlos is a PTHrP analog, whereas Forteo is a recombinant human PTH analog [6]. Clinical studies have shown that both drugs can effectively reduce fracture risk, with some studies suggesting comparable efficacy in increasing bone mineral density [7].
What are the potential side effects of Tymlos?
Common side effects of Tymlos include hypercalcemia, nausea, diarrhea, headache, and fatigue [2][5]. A boxed warning is associated with Tymlos, advising of the potential risk of osteosarcoma, a type of bone cancer, based on findings in animal studies [2][5]. Patients with a history of bone metastases or skeletal radiation should not use Tymlos [2].